Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699498 | 0.92 | EPHX1 (0.44) | MAPTSLC18A3CES1LMNAPOLB | |
| SCHEMBL9778785 | 0.83 | CA12 (0.53) | MAPTALDH1A1KMT2AMEN1RECQL | |
| SCHEMBL27828507 | 0.80 | KDM4E (0.47) | MAPTSLC18A3CES1LMNAPOLB | |
| SCHEMBL27828506 | 0.80 | KDM4E (0.47) | MAPTSLC18A3CES1LMNAPOLB | |
| SCHEMBL9451018 | 0.79 | MEN1 (0.41) | MAPTLMNAPOLBALDH1A1KMT2A | |
| SCHEMBL6347480 | 0.79 | MAPT (0.43) | MAPTSLC18A3LMNAPOLBGAA | |
| SCHEMBL9636565 | 0.79 | SMN1; SMN2 (0.53) | MAPTSLC18A3LMNAPOLBKDM4E | |
| SCHEMBL28368682 | 0.77 | SLC18A3 (0.45) | MAPTSLC18A3CES1LMNAPOLB | |
| SCHEMBL28368681 | 0.77 | SLC18A3 (0.45) | MAPTSLC18A3CES1LMNAPOLB | |
| SCHEMBL28373802 | 0.77 | SLC18A3 (0.45) | MAPTSLC18A3CES1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57102980-A | — | — | None | — | — | JP | disclosed |
| CN-108349929-B | Tocotrienol derivatives, pharmaceutical compositions and methods of use in 5-lipoxygenase related disorders | 昂热大学 | 2022-01-11 | — | — | CN | disclosed |
| US-20190144413-A1 | TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES | FRIEDRICH-SCHILLER-UNIVERSITÄT JENA (DE) | 2019-05-16 | — | — | US | disclosed |
| EP-3341366-A1 | TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES | Université d'Angers (FR) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017032881-A1 | TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES | Université d'Angers (FR) | 2017-03-02 | — | — | WO | disclosed |
| WO-2005011661-A1 | PHARMACEUTICAL AGENTS | UNIVERSITY COLLEGE LONDON (GB) | 2005-02-10 | — | — | WO | disclosed |
| JP-S57102980-A | LIQUID CRYSTAL COMPOSITION | SEIKO EPSON CORP | 1982-06-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144413-A1 | TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES | ALOX5, ALOX15B, ALOX15 | MAPT 4095/4885SLC18A3 2662/4885CES1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.